Iron storage “spheres” inside the bacterium C. diff — the leading cause of hospital-acquired infections — could offer new targets for antibacterial drugs to combat the pathogen. A team of Vanderbilt ...

C. diff colitis is inflammation of a person’s colon due to contagious bacteria. Most people with C. diff colitis fully recover, but in rare cases the condition can be life threatening. It is possible ...

TUESDAY, August 5, 2025 (HealthDay News) — C. diff, which is short for Clostridioides difficile, is a type of bacteria that may cause serious problems in the digestive system. It is one of the most ...

Recurrent C. diff infection is when you contract a C. diff infection 2 to 8 weeks after completing treatment for a previous one. C. diff relapse is a recurrence of the same strain, while reinfection ...

Rachel works as a CRNA where she provides anesthesia care across the lifespan, including pediatric anesthesia, with a primary focus on orthopedic anesthesia. She is also an Assistant Professor at the ...

Ten years after an outbreak of Clostridium difficile killed as many as 2000 people in Quebec, the diarrhea-causing bacterium is infecting fewer people in Canadian hospitals, though it remains a major ...

Some people will get repeat infections from Clostridium difficile (C. diff). They may develop the same symptoms they had before such as diarrhea, stomach pain, and loss of appetite. However, the only ...

Clostridium difficile bacteria, computer illustration. C. difficile is a normal inhabitant of the human intestine, but it can become a pathogen when antibiotics disrupt the normal intestinal flora and ...

Matthew Munneke, left, and Eric Skaar, PhD, MPH, use anaerobic chambers to study bacteria like C. diff that die in the presence of oxygen. The pathogen C. diff — the most common cause of health ...

Every year, the medical community recognizes the month of November as Clostridioides difficile (C. diff) Awareness month. C. diff is a public health threat that causes around 500,000 infections every ...

There are inherent risks in biotech investing. A decade’s worth and often hundreds of millions of dollars in R&D, along with binary risks of failed clinical trials or regulatory approval. Above and ...